Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Prospective, single-arm, open label, multicentre, phase II pilot study to evaluate the immediate and short term (one month) impact of a new long acting double bronchodilator on innovative parameters in stable and moderate to severe COPD patients.
The relationship with changes in dyspnea and conventional pulmonary function tests is the second aim of study.
After baseline assessment of these parameters, clinical and lung function evaluation will be performed 2 hours post-drug (peak drug effects). Patients will continue treatment with PT003 for 4 weeks. On Day 30, the same clinical and lung function assessments will be performed pre (trough) and 2h-post dose in order to obtain after-treatment measurements.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
35 participants in 1 patient group
Loading...
Central trial contact
Thierry PEREZ, MD,PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal